232 completed. 232 Phase 3, 26 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 232 | Completed 232 |
| Phase 2 | 26 | Completed 26 |
Follow Prostate Cancer: new trials by email Literature Review of Prostate Cancer trials Research Report on Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer QLG1080 - Prostate Cancer | Phase 3 | Completed | Qilu Pharmaceutical Co., Ltd. | 111 | 2025-03-11 | 2026-09-03 |
| Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer Florastamin[18F] Injection - Prostate Cancer | Phase 3 | Completed | HTA Co., Ltd. | 131 | 2024-12-19 | 2026-09-25 |
| Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer Copper Cu 64 PSMA I&T - Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Completed | Curium US LLC | 235 | 2024-04-01 | 2026-02-18 |
| Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer [18F]Florastamin Injection - Prostate Cancer | Phase 3 | Completed | HTA Co., Ltd. | 287 | 2023-10-20 | 2026-09-29 |
| Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate Relugolix, Leuprolide Acetate - Prostate Cancer | Phase 3 | Completed | Sumitomo Pharma America, Inc. | 387 | 2023-01-28 | 2026-06-15 |
| Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate Triptorelin embonate 22.5 mg - Prostate Cancer | Phase 3 | Completed | Ipsen | 147 | 2022-08-30 | 2025-07-25 |
| Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed Cognitive Fusion TRUS Guided Prostate Biopsy (PROBIOP) PSMA PET guided prostate biopsy, MRI directed TRUS guided prostate biopsy - Prostate Cancer, Prostate Neoplasm | Phase 2 / Phase 3 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 217 | 2021-10-25 | 2025-08-07 |
| Study of Diagnostic Performance of [18F]CTT1057 in BCR [18F]CTT1057, [68Ga]Ga-PSMA-11 - Prostatic Neoplasms, Prostate Cancer | Phase 3 | Completed | Novartis Pharmaceuticals | 190 | 2021-09-30 | 2025-10-20 |
| 68Ga-PSMA-11 PET in Patients With Prostate Cancer Ga-PSMA-11 - Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Completed | University of Colorado, Denver | 39 | 2021-09-29 | 2023-11-13 |
| Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection [18F]CTT1057 - Prostatic Neoplasms, Prostate Cancer | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 195 | 2021-09-07 | 2025-10-07 |
| Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer [18F]PSMA-1007 - Prostate Cancer, Prostate Cancer Recurrent | Phase 3 | Completed | ABX advanced biochemical compounds GmbH | 136 | 2021-08-27 | 2025-07-15 |
| Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy Sugammadex 6 mg/kg, Sugammadex 4 mg/kg - Prostate Cancer, Neuromuscular Blockade | Phase 3 | Completed | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 34 | 2021-07-13 | 2023-01-25 |
| Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence rhPSMA-7.3 (18F) Injection, Positron emission tomography scan - Prostate Cancer | Phase 3 | Completed | Blue Earth Diagnostics | 391 | 2020-05-04 | 2025-09-22 |
| Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer. rhPSMA-7.3 (18F) Injection, Positron Emission Tomography scan - Prostate Cancer | Phase 3 | Completed | Blue Earth Diagnostics | 356 | 2020-03-02 | 2025-02-26 |
| A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer Nivolumab, Prednisone, Docetaxel - Prostate Cancer | Phase 3 | Completed | Bristol-Myers Squibb | 1030 | 2020-02-06 | 2025-06-12 |
| Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® LY01005 3.6 mg, ZOLADEX® 3.6 mg - Prostate Cancer | Phase 3 | Completed | Luye Pharma Group Ltd. | 290 | 2020-01-06 | 2021-08-26 |
| [18F]PSMA-11 PET/CT Phase 3 Clinical Study [18F]PSMA-11, [68Ga]PSMA-11 - Prostate Cancer | Phase 3 | Completed | University Hospital, Ghent | 96 | 2019-04-01 | 2021-01-22 |
| F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence F-18-PSMA-1007, F-18-Fluorocholine - Prostate Cancer, Prostate Cancer Recurrent | Phase 3 | Completed | ABX advanced biochemical compounds GmbH | 200 | 2019-03-06 | 2021-06-29 |
| Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer 18F-DCFPyL, PET/CT Imaging - Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Completed | Progenics Pharmaceuticals, Inc. | 208 | 2018-11-27 | 2021-06-14 |
| Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients Ga-68 labeled PSMA-11, Positron emission tomography-computed tomography (PET/CT), Positron emission tomography-magnetic resonance imaging (PET/MRI) - Prostate Cancer | Phase 3 | Completed | Thomas Hope | 485 | 2018-10-11 | 2021-08-24 |
Showing 20 of 232. Sign in to see all of them.
Prostatic Neoplasms (232) · Neoplasms (12) · Neoplasm Metastasis (11) · Breast Neoplasms (7) · Pain (6) · Disease (5) · Osteoporosis (5) · Lung Neoplasms (4) · Carcinoma (3) · Carcinoma, Non-Small-Cell Lung (3) · Sexual Dysfunction, Physiological (3) · Anemia (2) · Bone Diseases, Metabolic (2) · Colonic Neoplasms (2) · Colorectal Neoplasms (2)
Genital Diseases (232) · Urogenital Diseases (232) · Genital Diseases, Male (230) · Genital Neoplasms, Male (230) · Male Urogenital Diseases (230) · Neoplasms by Site (230) · Prostatic Diseases (230) · Urogenital Neoplasms (230) · Neoplasms (220) · Pathological Conditions, Signs and Symptoms (29) · Pathologic Processes (21) · Neoplastic Processes (11) · Signs and Symptoms (11) · Breast Diseases (7) · Female Urogenital Diseases (7)
Goserelin (29) · Radiotherapy (28) · bicalutamide (27) · Leuprolide (24) · Prednisone (22) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (20) · Flutamide (17) · Docetaxel (15) · Gonadotropin-Releasing Hormone (10) · Triptorelin Pamoate (9) · Zoledronic Acid (8) · Androgen Antagonists (7) · Chemotherapy, Adjuvant (6) · Estramustine (6) · gallium 68 PSMA-11 (6)
Radiation Therapy Oncology Group (18) · Ferring Pharmaceuticals (17) · Alliance for Clinical Trials in Oncology (9) · SWOG Cancer Research Network (7) · UNICANCER (7) · European Organisation for Research and Treatment of Cancer - EORTC (5) · Abbott (4) · AstraZeneca (4) · NCIC Clinical Trials Group (4) · Novartis Pharmaceuticals (4) · Ontario Clinical Oncology Group (OCOG) (4) · Pfizer (4) · Amgen (3) · Blue Earth Diagnostics (3) · Bristol-Myers Squibb (3)
United States (124) · Canada (69) · France (48) · United Kingdom (38) · Netherlands (37) · Belgium (34) · Germany (34) · Italy (31) · Spain (29) · Australia (24) · Russia (23) · Poland (22) · Czechia (19) · Sweden (19) · Finland (18)
Eric J. Small, MD (4) · Michel Bolla, MD (4) · Thomas Hope, MD (4) · George Wilding, MD (3) · Daniel P. Petrylak, MD (2) · Gregory P. Swanson, MD (2) · Himu Lukka, MD (2) · Howard M. Sandler, MD (2)
PMID 34350976, PMID 38320143, PMID 25592642, PMID 24722180, PMID 29272162, PMID 33270906, PMID 36596347, PMID 36884035, PMID 21917607, PMID 23228299, PMID 24957547, PMID 25712310, PMID 26031410, PMID 29500065, PMID 33740734, PMID 33999161, PMID 35643841, PMID 35731340, PMID 35812443, PMID 37751207, PMID 10604271, PMID 10717606, PMID 10866876, PMID 10869758, PMID 11289126, PMID 11448906, PMID 11828353, PMID 12126818, PMID 12160582, PMID 12177096, PMID 12208577, PMID 12560440, PMID 12743142, PMID 12947070, PMID 14572748, PMID 14581419, PMID 14747052, PMID 15020604, PMID 15169799, PMID 15251156, PMID 15315996, PMID 15470214, PMID 15484217, PMID 15685244, PMID 15756004, PMID 15928300, PMID 16086912, PMID 16098367, PMID 16099293, PMID 16135479
2008 (6), 2009 (3), U10CA031946 (3), U10CA032102 (3), U10CA037429 (2), 2005 (1), 2015 (1), 2017 (1), 2018 (1), 2019 (1), P30CA006927 (1), P30CA008748 (1), P30CA016672 (1), P30CA023074 (1), R01CA077789 (1)